Bioventus (BVS) Financials

$9.28 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$9.27 -0.01 (-0.11%)

As of 05/22/2026 07:11 PM Eastern

Annual Income Statements for Bioventus

This table shows Bioventus' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	6.85	16	19	-159	-156	-36	23
Consolidated Net Income / (Loss)	6.30	15	9.59	-213	-196	-47	27
Net Income / (Loss) Continuing Operations	8.11	15	11	-145	-121	-47	27
Total Pre-Tax Income	9.69	16	9.49	-189	-121	-52	26
Total Operating Income	31	21	12	-167	-82	-15	54
Total Gross Profit	249	234	303	331	328	388	388
Total Revenue	340	321	431	512	512	573	568
Operating Revenue	-	321	431	512	512	573	568
Total Cost of Revenue	91	88	128	181	184	185	180
Operating Cost of Revenue	-	88	128	181	184	185	180
Total Operating Expenses	218	212	291	498	410	403	334
Selling, General & Admin Expense	198	193	254	332	304	344	314
Research & Development Expense	11	11	19	24	13	14	12
Depreciation Expense	7.91	7.44	8.36	9.75	8.84	7.65	5.73
Other Operating Expenses / (Income)	-	-	0.00	0.00	3.58	0.29	0.08
Impairment Charge	0.00	0.00	5.67	125	79	36	0.00
Restructuring Charge	0.58	0.56	2.49	6.78	0.84	-0.05	2.24
Other Special Charges / (Income)	0.00	0.00	0.83	1.10	0.72	1.42	0.00
Total Other Income / (Expense), net	-22	-5.32	-2.57	-22	-39	-37	-28
Interest Expense	-	-	-	-	0.00	0.00	0.33
Interest & Investment Income	-22	-9.75	-1.11	-12	-41	-39	-26
Other Income / (Expense), net	0.08	4.43	-1.46	-9.77	1.29	1.65	-1.45
Income Tax Expense	1.58	1.19	-1.97	-44	0.09	-5.29	-1.57
Net Income / (Loss) Discontinued Operations	-1.82	-	-1.87	-69	-74	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.55	-1.69	-9.79	-55	-39	-11	4.54
Basic Earnings per Share	$0.00	$0.00	($0.15)	($2.59)	($2.49)	($0.56)	$0.34
Weighted Average Basic Shares Outstanding	0.00	0.00	45.47M	61.39M	62.65M	64.55M	66.62M
Diluted Earnings per Share	$0.00	$0.00	($0.15)	($2.59)	($2.49)	($0.56)	$0.33
Weighted Average Diluted Shares Outstanding	0.00	0.00	45.47M	61.39M	62.65M	64.55M	68.91M
Weighted Average Basic & Diluted Shares Outstanding	-	-	76.39M	78.05M	79.17M	81.94M	83.15M

This table shows Bioventus' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/30/2024	6/29/2024	9/28/2024	12/31/2024	3/29/2025	6/28/2025	9/27/2025	12/31/2025	3/28/2026
Net Income / (Loss) Attributable to Common Shareholders	-7.30	-6.10	-4.89	-26	-5.17	-0.16	-2.64	7.46	3.16	15	3.11
Consolidated Net Income / (Loss)	-8.79	-7.66	-6.38	-34	-5.85	-0.32	-3.32	9.27	4.01	17	3.95
Net Income / (Loss) Continuing Operations	-8.79	-7.66	-6.38	-34	-5.85	-0.32	-3.32	9.27	4.01	17	3.95
Total Pre-Tax Income	-8.19	-8.41	-5.47	-42	-5.26	0.23	-3.42	10	4.67	14	4.52
Total Operating Income	2.42	1.17	4.93	-31	3.65	7.99	4.87	18	11	19	8.42
Total Gross Profit	79	86	88	104	94	103	83	102	94	109	91
Total Revenue	121	135	129	151	139	154	124	148	139	158	132
Operating Revenue	121	135	129	151	139	154	124	148	139	158	132
Total Cost of Revenue	42	49	41	48	45	51	41	46	44	49	41
Operating Cost of Revenue	42	49	41	48	45	51	41	46	44	49	41
Total Operating Expenses	76	85	83	135	90	95	78	84	83	89	82
Selling, General & Admin Expense	70	78	79	97	81	87	74	79	79	83	78
Research & Development Expense	3.02	3.26	2.63	4.21	3.84	3.25	3.01	3.17	2.92	3.01	2.47
Depreciation Expense	2.32	2.10	1.76	2.06	2.07	1.77	1.59	1.44	1.40	1.30	1.11
Other Operating Expenses / (Income)	1.40	-	0.00	0.00	0.00	-	0.08	0.00	-0.00	-	0.00
Restructuring Charge	-0.03	-0.07	-	-	-	-0.05	0.00	-	-	-	0.45
Total Other Income / (Expense), net	-11	-9.57	-10	-10	-8.91	-7.76	-8.29	-8.06	-6.58	-5.34	-3.90
Interest & Investment Income	-10	-10	-10	-9.92	-9.53	-9.00	-7.51	-7.49	-6.18	-5.31	-4.33
Other Income / (Expense), net	-0.49	0.71	-0.06	-0.16	0.63	1.24	-0.78	-0.56	-0.08	-0.04	0.43
Income Tax Expense	0.60	-0.75	0.91	-7.34	0.59	0.55	-0.10	1.04	0.66	-3.18	0.57
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.49	-1.56	-1.49	-8.54	-0.68	-0.16	-0.69	1.81	0.85	2.56	0.83
Basic Earnings per Share	($0.12)	($0.07)	($0.08)	($0.40)	($0.08)	($0.01)	($0.04)	$0.11	$0.05	$0.22	$0.05
Weighted Average Basic Shares Outstanding	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M	66.01M	66.50M	66.92M	66.62M	67.30M
Diluted Earnings per Share	($0.12)	($0.07)	($0.08)	($0.40)	($0.08)	($0.01)	($0.04)	$0.11	$0.05	$0.21	$0.04
Weighted Average Diluted Shares Outstanding	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M	66.01M	68.54M	68.84M	68.91M	70.01M
Weighted Average Basic & Diluted Shares Outstanding	78.75M	79.17M	79.61M	80.97M	81.15M	81.94M	82.14M	82.68M	82.76M	83.15M	83.53M

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	22	22	12	-67	5.13	4.62	9.66
Net Cash From Operating Activities	41	72	23	-14	15	39	75
Net Cash From Continuing Operating Activities	43	72	23	-11	18	39	75
Net Income / (Loss) Continuing Operations	8.11	15	11	-145	-121	-47	27
Consolidated Net Income / (Loss)	6.30	15	9.59	-213	-196	-47	27
Net Income / (Loss) Discontinued Operations	-1.82	-	-1.87	-69	-74	0.00	0.00
Depreciation Expense	30	29	35	55	57	50	47
Non-Cash Adjustments To Reconcile Net Income	16	12	0.15	153	84	49	14
Changes in Operating Assets and Liabilities, net	-12	17	-23	-75	-3.13	-13	-14
Net Cash From Discontinued Operating Activities	-1.83	-0.40	0.00	-2.13	-2.17	0.00	0.00
Net Cash From Investing Activities	-7.91	-21	-284	-116	16	23	-3.25
Net Cash From Continuing Investing Activities	-7.91	-21	-284	-12	27	23	-3.25
Purchase of Property, Plant & Equipment	-2.34	-17	-14	-1.48	-7.36	-1.01	-2.56
Acquisitions	0.43	-4.09	-270	-10	0.00	-0.71	0.00
Other Investing Activities, net	-	0.00	0.00	-0.08	35	25	-0.69
Net Cash From Discontinued Investing Activities	0.00	0.17	0.00	-105	-12	0.00	0.00
Net Cash From Financing Activities	-11	-30	273	62	-27	-55	-62
Net Cash From Continuing Financing Activities	-11	-30	273	62	-27	-55	-62
Repayment of Debt	-200	-59	-112	-45	-91	-62	-121
Issuance of Debt	198	49	277	105	64	0.00	77
Issuance of Common Equity	0.00	0.00	109	5.82	0.78	2.44	2.07
Other Financing Activities, net	-	0.00	0.00	-3.35	0.00	4.50	-20
Effect of Exchange Rate Changes	-0.10	0.59	-0.23	0.52	0.63	-2.56	0.37

This table details how cash moves in and out of Bioventus' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/30/2024	6/29/2024	9/28/2024	12/31/2024	3/29/2025	6/28/2025	9/27/2025	12/31/2025	3/28/2026
Net Change in Cash & Equivalents	-2.56	10	-12	6.82	11	-1.49	-19	10	9.25	9.07	-15
Net Cash From Operating Activities	-8.32	10	-6.01	15	10	19	-19	26	30	38	8.93
Net Cash From Continuing Operating Activities	-8.32	10	-6.01	15	10	19	-19	26	30	38	8.93
Net Income / (Loss) Continuing Operations	-8.79	-7.66	-6.38	-32	-5.42	-0.32	-3.32	9.27	4.01	17	3.95
Consolidated Net Income / (Loss)	-8.79	-7.66	-6.38	-32	-5.42	-0.32	-3.32	9.27	4.01	17	3.95
Depreciation Expense	14	12	12	13	12	12	12	12	11	12	11
Non-Cash Adjustments To Reconcile Net Income	2.70	1.83	2.39	36	3.35	4.53	2.90	3.71	3.63	3.73	3.55
Changes in Operating Assets and Liabilities, net	-16	3.73	-14	-1.96	0.11	2.70	-31	0.90	11	5.23	-9.77
Net Cash From Investing Activities	-2.04	-0.59	-1.00	-0.08	-0.06	24	-0.83	-1.37	-0.47	-0.58	-0.57
Net Cash From Continuing Investing Activities	-2.04	-0.59	-1.00	-0.08	-0.06	24	-0.83	-1.37	-0.47	-0.58	-0.57
Purchase of Property, Plant & Equipment	-2.04	-0.37	-0.29	-0.08	-0.06	-0.57	-0.83	-0.68	-0.47	-0.58	-0.57
Net Cash From Financing Activities	8.23	-0.01	-4.24	-7.85	0.36	-43	0.95	-15	-20	-28	-23
Net Cash From Continuing Financing Activities	8.23	-0.01	-4.24	-7.85	0.36	-43	0.95	-15	-20	-28	-23
Repayment of Debt	-7.17	-3.83	-4.42	-8.45	-0.19	-50	-5.20	-5.21	-81	-30	-22
Issuance of Debt	15	-	0.00	-	-	-	15	-	62	-	0.00
Issuance of Common Equity	0.40	0.16	0.18	0.61	0.55	1.10	0.15	1.32	0.10	0.51	0.12
Other Financing Activities, net	-	3.66	0.00	-	-	5.68	-9.00	-11	-0.71	0.70	-1.04
Effect of Exchange Rate Changes	-0.44	0.37	-0.54	-0.42	0.47	-2.06	0.43	0.20	-0.39	0.13	-0.61

This table presents Bioventus' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	494	1,226	1,373	811	728	684
Total Current Assets	212	263	273	268	276	273
Cash & Equivalents	87	44	30	37	42	51
Accounts Receivable	88	125	136	123	127	128
Inventories, net	29	62	85	91	92	82
Prepaid Expenses	7.55	27	19	17	14	11
Plant, Property, & Equipment, net	6.88	23	27	37	27	22
Total Noncurrent Assets	276	940	1,073	506	421	389
Long-Term Investments	19	29	2.62	3.14	1.89	2.29
Goodwill	50	148	7.46	7.46	7.46	7.46
Intangible Assets	192	695	640	482	405	368
Noncurrent Deferred & Refundable Income Taxes	0.00	0.48	-	-	-	5.52
Other Noncurrent Operating Assets	15	67	17	13	6.51	5.12
Total Liabilities & Shareholders' Equity	494	1,226	1,373	811	728	684
Total Liabilities	350	692	960	590	542	455
Total Current Liabilities	123	181	304	175	210	160
Short-Term Debt	15	18	33	28	47	15
Accounts Payable	4.42	17	37	23	24	11
Accrued Expenses	88	131	112	120	136	130
Other Current Liabilities	3.93	3.56	3.61	4.82	3.92	4.21
Total Noncurrent Liabilities	228	511	656	414	332	295
Long-Term Debt	173	340	385	367	308	279
Noncurrent Deferred & Payable Income Tax Liabilities	3.36	134	2.25	1.21	0.56	0.43
Other Noncurrent Operating Liabilities	22	38	40	46	23	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	144	534	412	221	186	228
Total Preferred & Common Equity	0.00	459	325	174	148	184
Total Common Equity	0.00	459	325	174	148	184
Common Stock	0.00	465	491	494	508	521
Retained Earnings	0.00	-6.60	-165	-322	-358	-335
Accumulated Other Comprehensive Income / (Loss)	0.00	0.18	-0.11	0.79	-2.57	-1.90
Noncontrolling Interest	144	75	87	48	38	44

This table presents Bioventus' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	10/1/2022	4/1/2023	7/1/2023	9/30/2023	3/30/2024	6/29/2024	9/28/2024	3/29/2025	6/28/2025	9/27/2025	3/28/2026
Total Assets	1,398	887	837	811	794	792	769	691	707	702	651
Total Current Assets	271	309	261	249	266	309	299	249	275	281	250
Cash & Equivalents	34	47	29	27	25	32	43	23	33	42	36
Accounts Receivable	132	119	120	113	126	137	122	118	132	130	121
Inventories, net	77	88	96	98	97	88	90	94	96	96	83
Prepaid Expenses	28	17	15	12	18	24	17	14	13	12	10
Plant, Property, & Equipment, net	0.00	37	42	40	35	32	29	26	25	23	21
Total Noncurrent Assets	1,127	542	534	522	494	451	441	416	407	398	379
Long-Term Investments	13	2.62	6.54	6.86	3.21	2.09	1.93	1.76	1.69	2.27	2.10
Goodwill	15	7.46	7.46	7.46	7.46	7.46	7.46	7.46	7.46	7.46	7.46
Intangible Assets	1,056	516	505	493	471	425	415	396	387	377	360
Noncurrent Deferred & Refundable Income Taxes	0.00	-	-	-	-	6.88	7.40	4.75	4.75	4.75	5.52
Other Noncurrent Operating Assets	43	16	15	14	12	10	9.78	6.63	6.23	5.83	4.69
Total Liabilities & Shareholders' Equity	1,398	887	837	811	794	792	769	691	707	702	651
Total Liabilities	1,019	647	604	585	577	603	583	506	505	494	416
Total Current Liabilities	288	196	179	161	173	231	211	175	186	162	148
Short-Term Debt	31	41	11	20	36	57	58	48	43	11	19
Accounts Payable	19	33	41	18	19	24	17	19	24	27	24
Accrued Expenses	117	116	122	119	114	140	129	103	114	119	101
Other Current Liabilities	121	6.15	4.67	4.73	4.81	9.74	8.15	4.36	4.41	4.41	4.16
Total Noncurrent Liabilities	731	451	425	424	403	372	371	331	320	333	268
Long-Term Debt	393	404	375	375	355	345	345	309	298	311	253
Noncurrent Deferred & Payable Income Tax Liabilities	159	0.35	0.00	0.00	1.29	0.00	0.00	0.61	0.65	0.79	0.57
Other Noncurrent Operating Liabilities	178	46	50	49	47	27	26	22	21	20	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	379	240	233	226	217	189	187	185	201	207	234
Total Preferred & Common Equity	343	189	183	178	171	151	149	148	161	166	189
Total Common Equity	343	189	183	178	171	151	149	148	161	166	189
Common Stock	478	493	491	493	497	501	503	511	515	518	523
Retained Earnings	-133	-304	-308	-315	-326	-350	-355	-360	-353	-350	-332
Accumulated Other Comprehensive Income / (Loss)	-1.34	0.41	0.66	0.40	0.33	-0.02	0.45	-2.06	-0.77	-1.84	-2.28
Noncontrolling Interest	36	52	50	49	46	38	38	37	40	41	45

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	75,224,819.00	-	-	-	82,763,214.00
DEI Adjusted Shares Outstanding	0.00	0.00	75,224,819.00	-	-	-	82,763,214.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.26	-	-	-	0.27
Growth Metrics	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	26	20	15	-117	-57	-8.39	57
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-14.10%	-9.29%	-1.55%	10.96%
Earnings before Interest and Taxes (EBIT)	31	26	11	-177	-80	-10	53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	62	54	45	-122	-23	39	100
Valuation Ratios	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-207	-572	-41	104	75	87
Efficiency Ratios	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	226	813	737	576	493	463
Increase / (Decrease) in Invested Capital	0.00	226	587	-76	-161	-83	-29
Book Value per Share	$0.00	$0.00	$6.10	$4.18	$2.20	$1.82	$2.22
Tangible Book Value per Share	$0.00	($30.18)	($5.10)	($4.14)	($4.02)	($3.26)	($2.32)
Total Capital	0.00	333	891	830	616	541	522
Total Debt	0.00	188	358	418	395	355	294
Total Long-Term Debt	0.00	173	340	385	367	308	279
Net Debt	0.00	82	279	385	355	312	240
Capital Expenditures (CapEx)	2.34	17	14	1.48	7.36	1.01	2.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	17	51	-29	83	71	76
Debt-free Net Working Capital (DFNWC)	0.00	104	100	1.61	120	112	127
Net Working Capital (NWC)	0.00	89	82	-31	93	65	112
Net Nonoperating Expense (NNE)	20	4.92	4.97	96	138	35	30
Net Nonoperating Obligations (NNO)	0.00	82	279	324	355	307	235
Total Depreciation and Amortization (D&A)	30	29	35	55	57	50	47
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.15)	($2.59)	($2.49)	($0.52)	$0.34
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	45.47M	61.39M	62.65M	64.55M	66.62M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.15)	($2.59)	($2.49)	($0.52)	$0.33
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	45.47M	61.39M	62.65M	64.55M	68.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	76.39M	78.05M	79.17M	81.94M	83.15M
Normalized Net Operating Profit after Tax (NOPAT)	27	20	15	-24	-1.09	18	39
Debt Service Ratios	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Bioventus' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/30/2024	6/29/2024	9/28/2024	12/31/2024	3/29/2025	6/28/2025	9/27/2025	12/31/2025	3/28/2026
DEI Shares Outstanding	-	-	-	-	-	-	81,943,605.00	82,144,347.00	82,679,040.00	82,763,214.00	83,154,789.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	81,943,605.00	82,144,347.00	82,679,040.00	82,763,214.00	83,154,789.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.03	0.09	0.04	0.18	0.04
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.12%	7.62%	8.73%	10.32%	15.04%	13.45%	-4.31%	-2.35%	-0.23%	-	6.63%
EBITDA Growth	113.89%	276.83%	123.04%	-178.88%	7.77%	50.88%	-4.16%	261.02%	36.43%	-	25.64%
EBIT Growth	101.52%	107.48%	105.82%	-573.42%	144.28%	392.48%	-15.89%	156.29%	161.48%	-	116.10%
NOPAT Growth	101.91%	107.45%	105.79%	-535.08%	68.49%	-1,442.62%	-1.20%	174.96%	278.09%	-	115.71%
Net Income Growth	93.97%	82.94%	96.57%	-578.76%	38.33%	95.85%	47.94%	127.10%	168.50%	-	218.78%
EPS Growth	93.18%	86.79%	96.88%	-516.67%	41.67%	85.71%	50.00%	127.50%	162.50%	-	200.00%
Operating Cash Flow Growth	-1,086.16%	97.83%	-341.16%	40.45%	224.06%	86.25%	-221.92%	71.07%	191.76%	-	146.22%
Free Cash Flow Firm Growth	131.93%	147.52%	-53.43%	-97.07%	-73.25%	-55.26%	11.59%	1,438.41%	52.10%	-	-14.92%
Invested Capital Growth	-22.32%	-21.83%	-8.79%	-4.51%	-7.28%	-14.46%	-10.83%	-8.81%	-10.88%	-	-9.48%
Revenue Q/Q Growth	-11.87%	12.11%	-4.41%	16.81%	-8.10%	10.56%	-19.37%	19.20%	-6.10%	-	-16.35%
EBITDA Q/Q Growth	-24.41%	-8.96%	18.90%	-196.41%	203.27%	27.45%	-26.24%	87.10%	-24.38%	-	-35.63%
EBIT Q/Q Growth	-69.15%	-2.60%	180.90%	-660.92%	115.92%	96.36%	-55.66%	335.17%	-37.26%	-	-54.53%
NOPAT Q/Q Growth	-64.18%	-51.82%	357.25%	-651.30%	113.87%	-483.94%	131.13%	384.52%	-41.55%	-	-69.19%
Net Income Q/Q Growth	-85.82%	12.91%	21.87%	-436.81%	83.12%	94.13%	-944.65%	379.11%	-56.79%	-	-77.21%
EPS Q/Q Growth	-100.00%	41.67%	0.00%	-428.57%	81.08%	85.71%	-300.00%	375.00%	-54.55%	-	-80.95%
Operating Cash Flow Q/Q Growth	-177.03%	224.76%	-157.89%	352.49%	-31.96%	87.30%	-200.05%	234.18%	16.04%	-	-76.47%
Free Cash Flow Firm Q/Q Growth	-13.09%	-5.15%	-63.09%	-90.39%	694.80%	58.63%	-8.37%	-1.04%	5.05%	-	18.51%
Invested Capital Q/Q Growth	0.70%	-1.96%	0.77%	-4.01%	-2.22%	-9.56%	5.04%	-1.83%	-4.44%	-	-0.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.28%	63.73%	68.27%	68.54%	67.32%	66.82%	67.05%	69.14%	67.96%	-	68.72%
EBITDA Margin	13.04%	10.59%	13.17%	-10.87%	12.22%	14.08%	12.88%	20.22%	16.28%	-	15.18%
Operating Margin	2.00%	0.86%	4.11%	-19.42%	2.93%	5.20%	3.93%	12.44%	8.12%	-	6.37%
EBIT Margin	1.59%	1.38%	4.07%	-19.53%	3.38%	6.01%	3.30%	12.06%	8.06%	-	6.69%
Profit (Net Income) Margin	-7.28%	-5.65%	-4.62%	-21.24%	-3.90%	-0.21%	-2.68%	6.28%	2.89%	-	2.99%
Tax Burden Percent	107.33%	91.08%	117.87%	81.40%	112.19%	-137.07%	97.22%	89.91%	85.78%	-	87.36%
Interest Burden Percent	-425.73%	-448.56%	-96.41%	133.61%	-102.81%	2.51%	-83.50%	57.92%	41.80%	-	51.08%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	237.07%	0.00%	10.09%	14.22%	-	12.64%
Return on Invested Capital (ROIC)	1.05%	0.47%	2.48%	-12.80%	2.01%	-7.65%	2.85%	11.85%	7.62%	-	6.51%
ROIC Less NNEP Spread (ROIC-NNEP)	-1.79%	-2.02%	-0.08%	-16.02%	-0.29%	-4.43%	0.91%	9.70%	5.85%	-	5.30%
Return on Net Nonoperating Assets (RNNOA)	-2.18%	-2.17%	-0.14%	-27.23%	-0.50%	-7.21%	1.57%	16.77%	9.43%	-	7.15%
Return on Equity (ROE)	-1.14%	-1.70%	2.34%	-40.03%	1.51%	-14.86%	4.41%	28.61%	17.05%	-	13.66%
Cash Return on Invested Capital (CROIC)	14.85%	15.79%	11.00%	2.10%	5.23%	14.02%	9.92%	13.23%	19.03%	-	21.93%
Operating Return on Assets (OROA)	0.73%	0.65%	2.53%	-12.87%	2.38%	4.48%	2.52%	9.08%	6.18%	-	5.75%
Return on Assets (ROA)	-3.31%	-2.65%	-2.87%	-14.00%	-2.74%	-0.15%	-2.05%	4.73%	2.21%	-	2.57%
Return on Common Equity (ROCE)	-0.98%	-1.34%	1.84%	-31.66%	1.19%	-11.75%	3.50%	22.88%	13.62%	-	10.97%
Return on Equity Simple (ROE_SIMPLE)	-131.16%	0.00%	-15.86%	-36.14%	-34.40%	0.00%	-27.52%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	1.69	0.82	3.73	-21	2.85	-11	3.41	17	9.65	24	7.35
NOPAT Margin	1.40%	0.60%	2.88%	-13.59%	2.05%	-7.13%	2.75%	11.18%	6.96%	-	5.57%
Net Nonoperating Expense Percent (NNEP)	2.84%	2.49%	2.56%	3.22%	2.30%	-3.21%	1.94%	2.15%	1.78%	-	1.20%
Return On Investment Capital (ROIC_SIMPLE)	-	0.13%	-	-	-	-2.02%	0.63%	3.04%	1.82%	4.57%	1.45%
Cost of Revenue to Revenue	34.72%	36.27%	31.73%	31.46%	32.68%	33.18%	32.95%	30.86%	32.04%	-	31.28%
SG&A Expenses to Revenue	57.80%	57.86%	60.57%	62.68%	58.35%	56.37%	59.34%	53.58%	56.73%	-	59.30%
R&D to Revenue	2.50%	2.41%	2.01%	2.64%	2.74%	2.11%	2.43%	2.15%	2.11%	-	1.87%
Operating Expenses to Revenue	63.27%	62.87%	64.15%	87.96%	64.39%	61.62%	63.12%	56.70%	59.85%	-	62.35%
Earnings before Interest and Taxes (EBIT)	1.92	1.87	5.26	-30	4.70	9.23	4.09	18	11	19	8.84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	14	17	-16	17	22	16	30	23	31	20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.46	2.39	2.40	3.03	6.34	5.76	4.99	3.45	3.32	-	3.94
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Price to Revenue (P/Rev)	0.52	0.81	0.79	0.85	1.70	1.49	1.30	0.99	0.98	-	1.29
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	300.28	54.13	-	26.10
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.33%	1.85%	-	3.83%
Enterprise Value to Invested Capital (EV/IC)	1.14	1.42	1.41	1.55	2.46	2.44	2.14	1.78	1.79	-	2.18
Enterprise Value to Revenue (EV/Rev)	1.33	1.60	1.57	1.61	2.41	2.10	1.95	1.60	1.54	-	1.77
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	12.07	28.14	41.92	30.63	28.79	10.39	9.36	-	9.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	53.64	0.00	0.00	0.00	0.00	23.55	19.23	-	17.86
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	74.87	0.00	0.00	0.00	0.00	42.22	22.45	-	17.32
Enterprise Value to Operating Cash Flow (EV/OCF)	65.51	53.26	119.82	77.02	44.84	30.97	43.55	24.91	15.53	-	9.94
Enterprise Value to Free Cash Flow (EV/FCFF)	6.71	7.89	12.27	72.15	45.25	16.04	20.38	12.82	8.88	-	9.46
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.74	1.79	1.80	2.13	2.16	1.91	1.92	1.70	1.56	-	1.16
Long-Term Debt to Equity	1.66	1.66	1.63	1.82	1.85	1.66	1.66	1.48	1.50	-	1.08
Financial Leverage	1.22	1.07	1.66	1.70	1.74	1.63	1.72	1.73	1.61	-	1.35
Leverage Ratio	3.65	3.45	3.67	3.86	3.82	3.78	3.69	3.84	3.73	-	3.20
Compound Leverage Factor	-15.53	-15.46	-3.54	5.15	-3.93	0.10	-3.08	2.22	1.56	-	1.63
Debt to Total Capital	63.54%	64.10%	64.28%	68.01%	68.31%	65.68%	65.78%	62.90%	60.88%	-	53.73%
Short-Term Debt to Total Capital	3.15%	4.52%	5.88%	9.70%	9.80%	8.67%	8.84%	7.99%	2.12%	-	3.70%
Long-Term Debt to Total Capital	60.38%	59.58%	58.39%	58.32%	58.51%	57.01%	56.94%	54.91%	58.76%	-	50.03%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	7.88%	7.72%	7.58%	6.45%	6.46%	6.96%	6.89%	7.38%	7.77%	-	8.96%
Common Equity to Total Capital	28.58%	28.18%	28.14%	25.54%	25.22%	27.36%	27.33%	29.72%	31.35%	-	37.31%
Debt to EBITDA	-8.67	-17.12	5.76	13.09	12.62	9.06	9.25	3.93	3.47	-	2.63
Net Debt to EBITDA	-7.93	-15.38	5.34	11.98	11.21	7.95	8.62	3.53	2.99	-	2.26
Long-Term Debt to EBITDA	-8.24	-15.91	5.23	11.23	10.81	7.86	8.01	3.43	3.35	-	2.44
Debt to NOPAT	-5.72	-6.90	35.69	-28.07	-30.61	-42.36	-42.31	15.96	8.33	-	4.61
Net Debt to NOPAT	-5.23	-6.20	33.10	-25.69	-27.19	-37.18	-39.39	14.34	7.18	-	3.96
Long-Term Debt to NOPAT	-5.44	-6.42	32.42	-24.07	-26.21	-36.77	-36.62	13.93	8.03	-	4.29
Altman Z-Score	0.48	0.64	0.67	0.51	1.20	1.20	1.12	0.99	1.03	-	1.48
Noncontrolling Interest Sharing Ratio	13.98%	21.24%	21.41%	20.90%	21.06%	20.95%	20.72%	20.03%	20.11%	-	19.70%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.55	1.53	1.53	1.33	1.41	1.31	1.43	1.48	1.74	-	1.69
Quick Ratio	0.87	0.91	0.87	0.73	0.78	0.80	0.81	0.89	1.07	-	1.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	170	162	60	5.74	46	72	66	66	69	53	56
Operating Cash Flow to CapEx	-408.40%	2,811.38%	-2,063.57%	19,690.91%	16,118.75%	3,366.20%	-2,340.31%	3,797.66%	6,363.21%	-	1,556.45%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	211.33	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	92.33	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	90.87	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.47	0.62	0.66	0.70	0.75	0.76	0.75	0.77	-	0.86
Accounts Receivable Turnover	4.10	3.96	4.28	4.18	4.73	4.58	4.66	4.18	4.47	-	4.83
Inventory Turnover	2.14	2.09	1.95	1.95	1.95	2.01	1.93	1.99	1.95	-	2.04
Fixed Asset Turnover	0.00	16.00	14.71	14.55	16.06	18.02	18.84	19.99	21.52	-	24.52
Accounts Payable Turnover	10.17	6.17	6.94	5.46	10.62	7.92	9.65	7.51	8.36	-	8.34
Days Sales Outstanding (DSO)	88.97	92.29	85.21	87.34	77.21	79.64	78.32	87.24	81.67	-	75.56
Days Inventory Outstanding (DIO)	170.61	174.52	187.43	186.73	186.89	181.27	188.68	183.78	187.02	-	179.27
Days Payable Outstanding (DPO)	35.89	59.20	52.62	66.82	34.36	46.08	37.82	48.61	43.67	-	43.74
Cash Conversion Cycle (CCC)	223.69	207.61	220.03	207.25	229.74	214.83	229.17	222.41	225.03	-	211.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	587	576	580	557	545	493	517	508	485	463	468
Invested Capital Turnover	0.75	0.78	0.86	0.94	0.98	1.07	1.03	1.06	1.09	-	1.17
Increase / (Decrease) in Invested Capital	-169	-161	-56	-26	-43	-83	-63	-49	-59	-29	-49
Enterprise Value (EV)	669	817	821	864	1,338	1,202	1,109	903	870	-	1,023
Market Capitalization	259	415	412	458	943	852	740	556	551	-	743
Book Value per Share	$2.26	$2.20	$2.16	$1.90	$1.84	$1.82	$1.81	$1.96	$2.01	$2.22	$2.27
Tangible Book Value per Share	($4.11)	($4.02)	($3.88)	($3.53)	($3.38)	($3.26)	($3.11)	($2.84)	($2.65)	($2.32)	($2.14)
Total Capital	621	616	609	591	590	541	542	543	530	522	506
Total Debt	395	395	391	402	403	355	357	341	323	294	272
Total Long-Term Debt	375	367	355	345	345	308	309	298	311	279	253
Net Debt	361	355	363	368	358	312	332	307	278	240	234
Capital Expenditures (CapEx)	2.04	0.37	0.29	0.08	0.06	0.57	0.83	0.68	0.47	0.58	0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)	81	83	103	103	102	71	100	100	88	76	85
Debt-free Net Working Capital (DFNWC)	108	120	128	135	145	112	123	133	130	127	120
Net Working Capital (NWC)	89	93	93	77	87	65	75	90	119	112	102
Net Nonoperating Expense (NNE)	10	8.47	9.71	12	8.27	-11	6.73	7.24	5.65	6.54	3.41
Net Nonoperating Obligations (NNO)	361	355	363	368	358	307	332	307	278	235	234
Total Depreciation and Amortization (D&A)	14	12	12	13	12	12	12	12	11	12	11
Debt-free, Cash-free Net Working Capital to Revenue	16.18%	16.28%	19.75%	19.14%	18.36%	12.31%	17.57%	17.72%	15.65%	-	14.68%
Debt-free Net Working Capital to Revenue	21.52%	23.49%	24.56%	25.09%	26.12%	19.56%	21.58%	23.55%	23.13%	-	20.90%
Net Working Capital to Revenue	17.62%	18.05%	17.71%	14.42%	15.71%	11.38%	13.14%	15.87%	21.13%	-	17.65%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)	($0.04)	$0.11	$0.05	$0.22	$0.05
Adjusted Weighted Average Basic Shares Outstanding	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M	66.01M	66.50M	66.92M	66.62M	67.30M
Adjusted Diluted Earnings per Share	($0.12)	($0.07)	($0.07)	($0.37)	($0.07)	($0.01)	($0.04)	$0.11	$0.05	$0.21	$0.04
Adjusted Weighted Average Diluted Shares Outstanding	62.82M	62.65M	63.38M	64.06M	65.26M	64.55M	66.01M	68.54M	68.84M	68.91M	70.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.75M	79.17M	79.61M	80.97M	81.15M	81.94M	82.14M	82.68M	82.76M	83.15M	83.53M
Normalized Net Operating Profit after Tax (NOPAT)	1.61	0.97	3.94	1.96	4.61	7.52	3.41	17	9.65	14	7.75
Normalized NOPAT Margin	1.33%	0.72%	3.04%	1.30%	3.32%	4.89%	2.75%	11.18%	6.96%	-	5.87%
Pre Tax Income Margin	-6.78%	-6.21%	-3.92%	-26.09%	-3.48%	0.15%	-2.76%	6.98%	3.37%	-	3.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	34.27	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.61	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.82	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28.16	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, trend-focused summary of Bioventus (BVS) quarterly results from the last four years, based on the provided income statements, cash flow statements, and balance sheets. The bullets highlight the most important points for retail investors.

Q4 2025 revenue reached $157.9 million, up from $153.6 million in Q4 2024, indicating year-over-year growth.
Q4 2025 gross profit was $108.782 million, with a gross margin of about 68.9% (108.782 / 157.9), reflecting solid profitability at the gross level.
Q4 2025 operating income was $19.486 million, an operating margin near 12.3%, signaling meaningful operating profitability.
Q4 2025 net income attributable to common shareholders was $14.755 million, a positive quarterly bottom line.
Q4 2025 cash flow from continuing operating activities was $37.968 million, indicating strong cash generation from core operations.
Q4 2025 net change in cash and equivalents was a positive $9.074 million, showing overall cash generation despite financing/investing activity.
Balance sheet snapshot (Q3 2025): Total assets about $701.593 million; total liabilities about $494.338 million; total equity and noncontrolling interests about $207.255 million.
Net cash from financing activities in Q4 2025 was negative $28.447 million, indicating cash outflows from financing activities (e.g., debt repayments and other financing).
Notable one-off impairment charges in some quarters (e.g., $124.697 million impairment in Q3 2023), which weigh on earnings in those periods.
Profitability has been volatile, with quarters showing net losses (e.g., Q1 2025 continuing net income of -$3.322 million; Q3 2023 continuing net income of -$8.791 million), suggesting earnings variability.

05/25/26 11:04 PM ETAI Generated. May Contain Errors.

Bioventus Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bioventus' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Bioventus' net income appears to be on an upward trend, with a most recent value of $27.27 million in 2025, rising from $6.30 million in 2019. The previous period was -$47.05 million in 2024. View Bioventus' forecast to see where analysts expect Bioventus to go next.

Bioventus' total operating income in 2025 was $53.98 million, based on the following breakdown:

Total Gross Profit: $388.16 million
Total Operating Expenses: $334.18 million

Over the last 6 years, Bioventus' total revenue changed from $340.14 million in 2019 to $568.09 million in 2025, a change of 67.0%.

Bioventus' total liabilities were at $455.11 million at the end of 2025, a 16.1% decrease from 2024, and a 29.9% increase since 2020.

In the past 5 years, Bioventus' cash and equivalents has ranged from $30.19 million in 2022 to $86.84 million in 2020, and is currently $51.24 million as of their latest financial filing in 2025.

Over the last 6 years, Bioventus' book value per share changed from 0.00 in 2019 to 2.22 in 2025, a change of 222.5%.

Related Companies

Financial statements for NASDAQ:BVS last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Financials

Financials Breakdown Chart

Key Financial Trends

Bioventus Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Financials

Annual Income Statements for Bioventus

Quarterly Income Statements for Bioventus

Annual Cash Flow Statements for Bioventus

Quarterly Cash Flow Statements for Bioventus

Annual Balance Sheets for Bioventus

Quarterly Balance Sheets for Bioventus

Annual Metrics And Ratios for Bioventus

Quarterly Metrics And Ratios for Bioventus

Financials Breakdown Chart

Key Financial Trends

Bioventus Financials - Frequently Asked Questions

When does Bioventus' fiscal year end?

How has Bioventus' net income changed over the last 6 years?

What is Bioventus' operating income?

How has Bioventus' revenue changed over the last 6 years?

How much debt does Bioventus have?

How much cash does Bioventus have?

How has Bioventus' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools